These filings can be found at www.sedar.com under the Company's profile.
About Zenith
. Metastatic Castration Resistant Prostate Cancer ('mCRPC') in combination with androgen receptor inhibitor, XTANDI
Triple Negative Breast Cancer in combination with the PARP inhibitor TALZENNA with
Androgen receptor independent mCRPC in combination with immune checkpoint inhibitor Keytruda and XTANDI Zenith Epigenetics is developing various novel combinations of
Contact:
Tel: 587-390-7865
Email: info@zenithepigenetics.com
Web: www.zenithepigenetics.com
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words 'believes', 'anticipates', 'plans', 'intends', 'will', 'should', 'expects', 'continue', 'estimate', 'forecasts' and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward -looking statements are subject to numerous assumptions and risk factors including those discussed in our most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. Zenith disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
(C) 2020 Electronic News Publishing, source